Phosphorylation of Profilin by ROCK1 Regulates Polyglutamine Aggregation

REFERENCES

• Amano, M., Y. Fukata, and K. Kaibuchi. 2000. Regulation and functions of Rho-associated kinase. Exp. Cell Res. 261:44–51.
   PubMed Web of Science ®Google Scholar
• Andreassen, O. A., A. Dedeoglu, R. J. Ferrante, B. G. Jenkins, K. L. Ferrante, M. Thomas, A. Friedlich, S. E. Browne, G. Schilling, D. R. Borchelt, S. M. Hersch, C. A. Ross, and M. F. Beal. 2001. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8:479–491.
   PubMed Web of Science ®Google Scholar
• Bamburg, J. R. 1999. Proteins of the ADF/cofilin family: essential regulators of actin dynamics. Annu. Rev. Cell Dev. Biol. 15:185–230.
   PubMed Web of Science ®Google Scholar
• Bjorkegren, C., M. Rozycki, C. E. Schutt, U. Lindberg, and R. Karlsson. 1993. Mutagenesis of human profilin locates its poly(L-proline)-binding site to a hydrophobic patch of aromatic amino acids. FEBS Lett. 333:123–126.
   PubMedGoogle Scholar
• Burnett, B. G., J. Andrews, S. Ranganathan, K. H. Fischbeck, and N. A. Di Prospero. 2008. Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamics. Neurobiol. Dis. 30:365–374.
   PubMedGoogle Scholar
• Chen, M., V. O. Ona, M. Li, R. J. Ferrante, K. B. Fink, S. Zhu, J. Bian, L. Guo, L. A. Farrell, S. M. Hersch, W. Hobbs, J. P. Vonsattel, J. H. Cha, and R. M. Friedlander. 2000. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6:797–801.
   PubMed Web of Science ®Google Scholar
• Da Silva, J. S., M. Medina, C. Zuliani, A. Di Nardo, W. Witke, and C. G. Dotti. 2003. RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability. J. Cell Biol. 162:1267–1279.
   PubMedGoogle Scholar
• Dedeoglu, A., J. K. Kubilus, T. M. Jeitner, S. A. Matson, M. Bogdanov, N. W. Kowall, W. R. Matson, A. J. Cooper, R. R. Ratan, M. F. Beal, S. M. Hersch, and R. J. Ferrante. 2002. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22:8942–8950.
   PubMed Web of Science ®Google Scholar
• Dehay, B., and A. Bertolotti. 2006. Critical role of the proline-rich region in huntingtin for aggregation and cytotoxicity in yeast. J. Biol. Chem. 281:35608–35615.
   PubMed Web of Science ®Google Scholar
• Desai, U. A., J. Pallos, A. A. Ma, B. R. Stockwell, L. M. Thompson, J. L. Marsh, and M. I. Diamond. 2006. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum. Mol. Genet. 15:2114–2124.
   PubMed Web of Science ®Google Scholar
• Diamond, M. I., M. R. Robinson, and K. R. Yamamoto. 2000. Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 97:657–661.
   PubMed Web of Science ®Google Scholar
• Ferrante, R. J., O. A. Andreassen, A. Dedeoglu, K. L. Ferrante, B. G. Jenkins, S. M. Hersch, and M. F. Beal. 2002. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22:1592–1599.
   PubMed Web of Science ®Google Scholar
• Ferrante, R. J., O. A. Andreassen, B. G. Jenkins, A. Dedeoglu, S. Kuemmerle, J. K. Kubilus, R. Kaddurah-Daouk, S. M. Hersch, and M. F. Beal. 2000. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20:4389–4397.
   PubMed Web of Science ®Google Scholar
• Ferrante, R. J., J. K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, K. Smith, N. W. Kowall, R. R. Ratan, R. Luthi-Carter, and S. M. Hersch. 2003. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23:9418–9427.
   PubMed Web of Science ®Google Scholar
• Fukata, Y., M. Amano, and K. Kaibuchi. 2001. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 22:32–39.
   PubMed Web of Science ®Google Scholar
• Gardian, G., S. E. Browne, D. K. Choi, P. Klivenyi, J. Gregorio, J. K. Kubilus, H. Ryu, B. Langley, R. R. Ratan, R. J. Ferrante, and M. F. Beal. 2005. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280:556–563.
   PubMed Web of Science ®Google Scholar
• Goehler, H., M. Lalowski, U. Stelzl, S. Waelter, M. Stroedicke, U. Worm, A. Droege, K. S. Lindenberg, M. Knoblich, C. Haenig, M. Herbst, J. Suopanki, E. Scherzinger, C. Abraham, B. Bauer, R. Hasenbank, A. Fritzsche, A. H. Ludewig, K. Bussow, S. H. Coleman, C. A. Gutekunst, B. G. Landwehrmeyer, H. Lehrach, and E. E. Wanker. 2004. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell 15:853–865.
   PubMed Web of Science ®Google Scholar
• Hockly, E., V. M. Richon, B. Woodman, D. L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal, P. A. Lowden, J. S. Steffan, J. L. Marsh, L. M. Thompson, C. M. Lewis, P. A. Marks, and G. P. Bates. 2003. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 100:2041–2046.
   PubMed Web of Science ®Google Scholar
• Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971–983.
   PubMed Web of Science ®Google Scholar
• Ishizaki, T., M. Naito, K. Fujisawa, M. Maekawa, N. Watanabe, Y. Saito, and S. Narumiya. 1997. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett. 404:118–124.
   PubMedGoogle Scholar
• Karpuj, M. V., M. W. Becher, J. E. Springer, D. Chabas, S. Youssef, R. Pedotti, D. Mitchell, and L. Steinman. 2002. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8:143–149.
   PubMed Web of Science ®Google Scholar
• Kawano, Y., Y. Fukata, N. Oshiro, M. Amano, T. Nakamura, M. Ito, F. Matsumura, M. Inagaki, and K. Kaibuchi. 1999. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J. Cell Biol. 147:1023–1038.
   PubMed Web of Science ®Google Scholar
• La Spada, A. R., E. M. Wilson, D. B. Lubahn, A. E. Harding, and K. H. Fischbeck. 1991. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77–79.
   PubMed Web of Science ®Google Scholar
• Leung, T., X. Q. Chen, E. Manser, and L. Lim. 1996. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell. Biol. 16:5313–5327.
   PubMed Web of Science ®Google Scholar
• Li, M., E. S. Chevalier-Larsen, D. E. Merry, and M. I. Diamond. 2007. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J. Biol. Chem. 282:3157–3164.
   PubMed Web of Science ®Google Scholar
• Maekawa, M., T. Ishizaki, S. Boku, N. Watanabe, A. Fujita, A. Iwamatsu, T. Obinata, K. Ohashi, K. Mizuno, and S. Narumiya. 1999. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285:895–898.
   PubMed Web of Science ®Google Scholar
• Mahoney, N. M., P. A. Janmey, and S. C. Almo. 1997. Structure of the profilin-poly-L-proline complex involved in morphogenesis and cytoskeletal regulation. Nat. Struct. Biol. 4:953–960.
   PubMedGoogle Scholar
• Mahoney, N. M., D. A. Rozwarski, E. Fedorov, A. A. Fedorov, and S. C. Almo. 1999. Profilin binds proline-rich ligands in two distinct amide backbone orientations. Nat. Struct. Biol. 6:666–671.
   PubMedGoogle Scholar
• Meriin, A. B., X. Zhang, I. M. Alexandrov, A. B. Salnikova, M. D. Ter-Avanesian, Y. O. Chernoff, and M. Y. Sherman. 2007. Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains. FASEB J. 21:1915–1925.
   PubMed Web of Science ®Google Scholar
• Metzler, W. J., A. J. Bell, E. Ernst, T. B. Lavoie, and L. Mueller. 1994. Identification of the poly-L-proline-binding site on human profilin. J. Biol. Chem. 269:4620–4625.
   PubMed Web of Science ®Google Scholar
• Muchowski, P. J., G. Schaffar, A. Sittler, E. E. Wanker, M. K. Hayer-Hartl, and F. U. Hartl. 2000. hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA 97:7841–7846.
   PubMed Web of Science ®Google Scholar
• Mueller, B. K., H. Mack, and N. Teusch. 2005. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 4:387–398.
   PubMed Web of Science ®Google Scholar
• Noma, K., N. Oyama, and J. K. Liao. 2006. Physiological role of ROCKs in the cardiovascular system. Am. J. Physiol. Cell Physiol. 290:C661–C668.
   PubMed Web of Science ®Google Scholar
• Ohashi, K., K. Nagata, M. Maekawa, T. Ishizaki, S. Narumiya, and K. Mizuno. 2000. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 275:3577–3582.
   PubMed Web of Science ®Google Scholar
• Ostrander, D. B., E. G. Ernst, T. B. Lavoie, and J. A. Gorman. 1999. Polyproline binding is an essential function of human profilin in yeast. Eur. J. Biochem. 262:26–35.
   PubMedGoogle Scholar
• Pollitt, S. K., J. Pallos, J. Shao, U. A. Desai, A. A. Ma, L. M. Thompson, J. L. Marsh, and M. I. Diamond. 2003. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40:685–694.
   PubMed Web of Science ®Google Scholar
• Riento, K., and A. J. Ridley. 2003. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4:446–456.
   PubMed Web of Science ®Google Scholar
• Ross, C. A., and M. A. Poirier. 2004. Protein aggregation and neurodegenerative disease. Nat. Med. 10(Suppl):S10–S17.
   PubMedGoogle Scholar
• Schilling, G., M. L. Coonfield, C. A. Ross, and D. R. Borchelt. 2001. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci. Lett. 315:149–153.
   PubMed Web of Science ®Google Scholar
• Schluter, K., B. M. Jockusch, and M. Rothkegel. 1997. Profilins as regulators of actin dynamics. Biochim. Biophys. Acta 1359:97–109.
   PubMed Web of Science ®Google Scholar
• Schluter, K., M. Schleicher, and B. M. Jockusch. 1998. Effects of single amino acid substitutions in the actin-binding site on the biological activity of bovine profilin I. J. Cell Sci. 111:3261–3273.
   PubMedGoogle Scholar
• Schutt, C. E., J. C. Myslik, M. D. Rozycki, N. C. Goonesekere, and U. Lindberg. 1993. The structure of crystalline profilin-beta-actin. Nature 365:810–816.
   PubMed Web of Science ®Google Scholar
• Shao, J., W. J. Welch, and M. I. Diamond. 2008. ROCK and PRK-2 mediate the inhibitory effect of Y-27632 on polyglutamine aggregation. FEBS Lett. 582:1637–1642.
   PubMedGoogle Scholar
• Singh, S. S., A. Chauhan, N. Murakami, J. Styles, M. Elzinga, and V. P. Chauhan. 1996. Phosphoinositide-dependent in vitro phosphorylation of profilin by protein kinase C. Phospholipid specificity and localization of the phosphorylation site. Recept. Signal Transduct. 6:77–86.
   PubMedGoogle Scholar
• Sumi, T., K. Matsumoto, and T. Nakamura. 2001. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J. Biol. Chem. 276:670–676.
   PubMed Web of Science ®Google Scholar
• Taylor, J. P., F. Tanaka, J. Robitschek, C. M. Sandoval, A. Taye, S. Markovic-Plese, and K. H. Fischbeck. 2003. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum. Mol. Genet. 12:749–757.
   PubMed Web of Science ®Google Scholar
• Uehata, M., T. Ishizaki, H. Satoh, T. Ono, T. Kawahara, T. Morishita, H. Tamakawa, K. Yamagami, J. Inui, M. Maekawa, and S. Narumiya. 1997. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389:990–994.
   PubMed Web of Science ®Google Scholar
• Vemuri, B., and S. S. Singh. 2001. Protein kinase C isozyme-specific phosphorylation of profilin. Cell. Signal. 13:433–439.
   PubMedGoogle Scholar
• Wang, X., S. Zhu, M. Drozda, W. Zhang, I. G. Stavrovskaya, E. Cattaneo, R. J. Ferrante, B. S. Kristal, and R. M. Friedlander. 2003. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc. Natl. Acad. Sci. USA 100:10483–10487.
   PubMed Web of Science ®Google Scholar
• Welch, W. J., and M. I. Diamond. 2001. Glucocorticoid modulation of androgen receptor nuclear aggregation and cellular toxicity is associated with distinct forms of soluble expanded polyglutamine protein. Hum. Mol. Genet. 10:3063–3074.
   PubMedGoogle Scholar
• Witke, W. 2004. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol. 14:461–469.
   PubMed Web of Science ®Google Scholar
• Witke, W., A. V. Podtelejnikov, A. Di Nardo, J. D. Sutherland, C. B. Gurniak, C. Dotti, and M. Mann. 1998. In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. EMBO J. 17:967–976.
   PubMed Web of Science ®Google Scholar
• Wittenmayer, N., B. Jandrig, M. Rothkegel, K. Schluter, W. Arnold, W. Haensch, S. Scherneck, and B. M. Jockusch. 2004. Tumor suppressor activity of profilin requires a functional actin binding site. Mol. Biol. Cell 15:1600–1608.
   PubMedGoogle Scholar
• Yarmola, E. G., and M. R. Bubb. 2006. Profilin: emerging concepts and lingering misconceptions. Trends Biochem. Sci. 31:197–205.
   PubMedGoogle Scholar